Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations

Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?

(2018) Theodore Karrison et al.   Clinical Trials

Hazards of Hazard Ratios — Deviations from Model Assumptions in Immunotherapy

(2018) Brian M. Alexander et al.   NEW ENGLAND JOURNAL OF MEDICINE

A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials

(2018) Miki Horiguchi et al.   STATISTICS IN MEDICINE

Application of multi-state models in cancer clinical trials

(2018) Jennifer G Le-Rademacher et al.   Clinical Trials

Design of non-inferiority randomized trials using the difference in restricted mean survival times

(2018) Isabelle R Weir et al.   Clinical Trials

Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment

(2018) I R Weir et al.   ANNALS OF ONCOLOGY

Avoiding the hazards of misinterpreting treatment effects

(2018) E D Saad et al.   ANNALS OF ONCOLOGY

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2017) Bart L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point

(2017) Bo Huang et al.   PHARMACEUTICAL STATISTICS

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

(2017) Kyongsun Pak et al.   JAMA Oncology

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

(2016) Patrick Royston et al.   BMC Medical Research Methodology

Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis

(2016) Béranger Lueza et al.   BMC Medical Research Methodology

Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?

(2016) Roger P. A’Hern   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials

(2016) Ludovic Trinquart et al.   JOURNAL OF CLINICAL ONCOLOGY

On the restricted mean survival time curve in survival analysis

(2015) Lihui Zhao et al.   BIOMETRICS

Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data

(2015) Yinghui Wei et al.   STATISTICS IN MEDICINE

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

(2013) Patrick Royston et al.   BMC Medical Research Methodology